MannKind | MNKD - Net Income


MannKind reported $-16.62M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Adma Biologics USD 45.33M 4.05M Mar/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Insmed USD -13.24M 150.32M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
MacroGenics USD -36.77M 22.62M Mar/2026
MannKind USD -16.62M 671K Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Novo Nordisk DKK 3.26B 45.29B Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Xencor USD -21.73M 107.19M Jun/2026